BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does BRIM Biotechnology Inc. (6885) operate in?
BRIM Biotechnology Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is BRIM Biotechnology Inc. (6885) current stock price?
As of the latest data, BRIM Biotechnology Inc. stock price is NT$30.15, with a previous close of NT$30.15.
What is BRIM Biotechnology Inc. (6885) current market capitalization?
BRIM Biotechnology Inc. market cap is approximately 3.96 billion.
What is BRIM Biotechnology Inc. (6885) Earnings Per Share (EPS)?
The trailing EPS is -NT$4.84.
Does BRIM Biotechnology Inc. (6885) pay dividends?
No. BRIM Biotechnology Inc. does not pay a dividend.
What is BRIM Biotechnology Inc. (6885) beta (volatility) score?
BRIM Biotechnology Inc. has a beta of 1.203, suggesting it is more volatile than the market.
